Mouth cancer
A Study to See if Low-Dose Nivolumab plus Oral Metronomic Chemotherapy helps Prevent Recurrence After Surgery in High-Risk Head and Neck Cancer Patients
Who can joinAdults
Age18+ years
Kind of studyPhase 2: does it work?
What it testsA medicine and radiation and surgery or a procedure
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)Navi MumbaiDirections ↗
Registry summary (technical)
A Phase II Randomized Trial of Adjuvant Low-Dose Nivolumab plus Oral Metronomic Chemotherapy in Resected High-Risk Head and Neck Squamous Cell Carcinoma - TEJAS-HN
Sponsor: ACTREC, TMC
CTRI/2026/05/110101 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 5 Oct 2026 · read by us 5 Nov 2026